Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer

Cancer

Volumn 118, Issue 12, 2012, Pages 3053-3061

  Epstein, Andrew S ^a   Soff, Gerald A ^a   Capanu, Marinela ^a   Crosbie, Christopher ^a   Shah, Manish A ^a   Kelsen, David P ^a   Denton, Brian ^a   Gardos, Stuart ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anticoagulation; Cancer; Incidence; Pancreas; Thrombosis

Indexed keywords

ALBUMIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; ERLOTINIB; ERYTHROPOIETIN STIMULATING AGENT; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMATOLOGIC AGENT; HEMOGLOBIN; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURVIVAL; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; AGED; BODY MASS INDEX; FEMALE; HEMATINICS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 82355193002     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26600     Document Type: Article

References (33)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu. Paris, France: Bailliere; 1865:654-712.
2. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6-12. (Pubitemid 32830510)
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339-2346. (Pubitemid 350100757)
4. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer. 2006;42:410-414. (Pubitemid 43132898)
5. Cubilla A, Fitzgerald PJ. Pancreas cancer. I. Duct adenocarcinoma. A clinical-pathologic study of 380 patients. Pathol Annu. 1978;13(pt 1):241-289.
6. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18:1660-1665. (Pubitemid 47506252)
7. Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995;130:125-134.
8. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res. 2008;122:485-490.
9. Pinzon R, Drewinko B, Trujillo JM, Guinee V, Giacco G. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol. 1986;4:509-514. (Pubitemid 16117940)
10. Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med. 1975;6:433-458.
11. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body and tail of the pancreas with multiple venous thrombosis. Am J Cancer. 1938;34:566-585.
12. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870-2875. (Pubitemid 46849560)
13. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531-2539. (Pubitemid 40569450)
14. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.
15. Moore R, Adel N, Bhutani M, et al. Cisplatin-based chemotherapy is associated with an unacceptably high incidence of thromboembolic events: a large retrospective analysis. Abstract presented at: American Society of Hematology, 51st Annual Meeting and Exhibition; December 5-8, 2009; New Orleans, La. Abstract #456.
16. Shah MA, Capanu M, Soff G, Asmis T, Kelsen D. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010;8:1702-1709.
17. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-5382.
18. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-464.
19. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850. (Pubitemid 32104130)
20. Piccioli A, Falanga A, Prandoni P. Anticoagulants and cancer survival. Semin Thromb Hemost. 2006;32:810-813. (Pubitemid 44956976)
21. Zacharski LR, Lee AY. Heparin as an anticancer therapeutic. Expert Opin Investig Drugs. 2008;17:1029-1037.
22. Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer. 2009;7(suppl):362.
23. Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol. 2010;28(15 suppl):4033.
24. van Doormaal FF, Di Nisio M, Otten H-M, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29:2071-2076.
25. Exocrine pancreas. In: Greene F, Page D, Fleming I, et al, eds. AJCC Cancer Staging Manual. New York, NY: Springer; 2010;24:241-250.
26. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29:2405-2409.
27. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
28. Delluc A, Mottier D, Le Gal G, Oger E, Lacut K. Underweight is associated with a reduced risk of venous thromboembolism. Results from the EDITH case-control study. J Thromb Haemost. 2009;7:728-729.
29. Andreotti F, Rio T, Lavorgna A. Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J. 2009;30:752-754.
30. Li Z, Webb WB, Mao J, Gautam S, Singh S, Lyman GH. Role of hypoalbuminemia in the development of venous thromboembolism in cancer chemotherapy patients [abstract]. J Clin Oncol. 2011. 29:Abstract #9032.
31. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010;104:1049-1054.
32. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15-20.
33. Dubin JA, Muller HG, Wang JL. Event history graphs for censored survival data. Stat Med. 2001;20:2951-2964. (Pubitemid 32923218)